Le Lézard
Classified in: Health
Subject: HEALTH

More than 6 drinks a week puts your health at risk: New Canada's Guidance on Alcohol and Health

OTTAWA, Jan. 17, 2023 (GLOBE NEWSWIRE) -- According to the new Canada's Guidance on Alcohol and Health, 3?6 standard drinks a week represents a moderate risk to your health. After that, the more you drink, the more you increase your risk of seven types of cancer, most types of cardiovascular diseases, liver disease and violence. The guidance recommends no more than 2 drinks a day (per occasion). The bottom line is that, when it comes to alcohol and your health, less is better.

Replacing the 2011 Low-Risk Alcohol Drinking Guidelines, the new guidance supports people in making informed decisions about their health. It meets people where they are at and gives them an opportunity to evaluate their drinking patterns.

To help illustrate the risks, the guidance presents a continuum of risk associated with drinking alcohol, allowing people to decide for themselves where they are comfortable being on that continuum. Basically, the more you drink, the higher your risk. The report suggests that:

"People have a right to know this information. The concept of a continuum of risk puts power in people's hands to make their own informed decisions," said Alexander Caudarella, Chief Executive Officer of the Canadian Centre on Substance Use and Addiction (CCSA). Caudarella, who is also a family physician specializing in substance use, continued, "The evidence is clear that every drink counts. It's also clear that it's never too late to make changes. Any reduction in alcohol use can be beneficial. Health professionals can now better determine an individual's risk and collaborate with their patients to improve their health."

Chief Executive Officer of the Canadian Cancer Society, Andrea Seale, agreed, saying, "Canadians need to know there are serious health risks associated with drinking alcohol, including elevated risk of multiple types of cancer. Many Canadians are unaware that alcohol consumption increases the risk of cancer, and most don't realize they are drinking unsafe amounts. This guidance is so important because it clarifies that the less alcohol you drink, the lower your cancer risk."

The two-year research project, led by CCSA, looked at nearly 6,000 peer-reviewed studies and involved an expert panel of 23 scientists representing 16 organizations. The guidance incorporates findings from focus groups and three consultations with the public and stakeholders. The most recent public consultation received nearly 1,000 survey submissions, all of which were diligently evaluated to ensure the guidance is clear and practical for those using it, including physicians, counsellors, community workers, policy makers and the public.

Media contact

Wendy Schlachta, Communications Advisor, Canadian Centre on Substance Use and Addiction
Tel.: 613-235-4048 ext. 285 I Email: media@ccsa.ca I Twitter: @CCSAcanada

CCSA was created by Parliament to provide national leadership to address substance use in Canada. A trusted counsel, we provide national guidance to decision makers by harnessing the power of research, curating knowledge and bringing together diverse perspectives.

CCSA activities and products are made possible through a financial contribution from Health Canada. The views of CCSA do not necessarily represent the views of the Government of Canada.

These press releases may also interest you

at 22:00
The bacterial disease diagnostics market size is forecast to grow by USD 3,766.05 million between 2022 and 2027. However, the growth momentum will be decelerating at a CAGR of 6.28% during the forecast period. The growth of the market is driven by...

at 21:18
Avirmax CMC Inc. (ACI), a cGMP-licensed CDMO, is announcing the implementation of its newly-developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVFtm) developed for producing recombinant adeno-associated viral vectors (rAAV)....

at 20:35
Biogen Inc.  announced today the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1...

at 20:30
The "Global Gene Editing Partnering Terms and Agreements 2010 to 2023" report has been added to  ResearchAndMarkets.com's offering. The Global Gene Editing Partnering Terms and Agreements 2010-2023 report provides an understanding and access to 400+...

at 20:01
Huma's platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health innovation across the industryClass IIb certification expands the patient population and level of...

at 20:00
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that two...

News published on 17 january 2023 at 08:00 and distributed by: